Recombinant Therapeutic Protein Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class ( Plasma Protein, Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Enzyme, Coagulation Factors, Others ); Application ( Oncology, Hematology, Immunology, Endocrinology, Cardiovascular Disease, Others )
Report Code: TIPRE00010928 No. of Pages: 150 Category: Biotechnology Status: Upcoming
MARKET INTRODUCTION
A recombinant protein therapy is fashioned through recombinant DNA technology, which deal with the insertion of the DNA encoding protein into mammalian or bacterial cells. Majority of the biologics, such as monoclonal antibodies, are recombinant protein therapies which are widely used for several health related conditions. Increasing number of research and development activities are projected to drive the market during the forecast period.
MARKET DYNAMICS
The Recombinant Therapeutic Protein Market growth is prominently attributed to increasing prevalence of chronic conditions. Additionally, growing awareness of benefits offered by these therapeutic proteins are also anticipated to drive the market growth.
MARKET SCOPE
The "Recombinant Therapeutic Protein Market Analysis to 2027" is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of Recombinant Therapeutic Protein Market with detailed market segmentation by drug class and application. The recombinant therapeutic protein market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Recombinant Therapeutic Protein Market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Recombinant Therapeutic Protein Market is segmented on the basis of drug class and application. Based on drug class, the market is segmented as plasma protein, growth factors, fusion proteins, monoclonal antibodies, hormones, enzyme, coagulation factors, and others. On the basis of applications, the market is categorized as oncology, hematology, immunology, endocrinology, cardiovascular disease, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Recombinant Therapeutic Protein Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Recombinant Therapeutic Protein Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Recombinant Therapeutic Protein Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Recombinant Therapeutic Protein Market in these regions.
The report covers key developments in the Recombinant Therapeutic Protein Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Recombinant Therapeutic Protein Market are anticipated to have lucrative growth opportunities in the future with the rising demand for radiotherapy devices in the global market. Below mentioned is the list of few companies engaged in the Recombinant Therapeutic Protein Market.
The report also includes the profiles of key players in Recombinant Therapeutic Protein Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
A recombinant protein therapy is fashioned through recombinant DNA technology, which deal with the insertion of the DNA encoding protein into mammalian or bacterial cells. Majority of the biologics, such as monoclonal antibodies, are recombinant protein therapies which are widely used for several health related conditions. Increasing number of research and development activities are projected to drive the market during the forecast period.
MARKET DYNAMICS
The Recombinant Therapeutic Protein Market growth is prominently attributed to increasing prevalence of chronic conditions. Additionally, growing awareness of benefits offered by these therapeutic proteins are also anticipated to drive the market growth.
MARKET SCOPE
The "Recombinant Therapeutic Protein Market Analysis to 2027" is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of Recombinant Therapeutic Protein Market with detailed market segmentation by drug class and application. The recombinant therapeutic protein market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Recombinant Therapeutic Protein Market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Recombinant Therapeutic Protein Market is segmented on the basis of drug class and application. Based on drug class, the market is segmented as plasma protein, growth factors, fusion proteins, monoclonal antibodies, hormones, enzyme, coagulation factors, and others. On the basis of applications, the market is categorized as oncology, hematology, immunology, endocrinology, cardiovascular disease, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Recombinant Therapeutic Protein Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Recombinant Therapeutic Protein Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Recombinant Therapeutic Protein Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Recombinant Therapeutic Protein Market in these regions.
The report covers key developments in the Recombinant Therapeutic Protein Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Recombinant Therapeutic Protein Market are anticipated to have lucrative growth opportunities in the future with the rising demand for radiotherapy devices in the global market. Below mentioned is the list of few companies engaged in the Recombinant Therapeutic Protein Market.
The report also includes the profiles of key players in Recombinant Therapeutic Protein Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Bristol-Myers Squibb
- Celldex Therapeutics, Inc.
- Eli Lilly and Company
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Novartis International AG
- Schering AG
- Johnson & Johnson
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Recombinant Therapeutic Protein Market - By Drug Class
1.3.2 Recombinant Therapeutic Protein Market - By Application
1.3.3 Recombinant Therapeutic Protein Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RECOMBINANT THERAPEUTIC PROTEIN MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RECOMBINANT THERAPEUTIC PROTEIN MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. RECOMBINANT THERAPEUTIC PROTEIN MARKET - GLOBAL MARKET ANALYSIS
6.1. RECOMBINANT THERAPEUTIC PROTEIN - GLOBAL MARKET OVERVIEW
6.2. RECOMBINANT THERAPEUTIC PROTEIN - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. RECOMBINANT THERAPEUTIC PROTEIN MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. PLASMA PROTEIN
7.3.1. Overview
7.3.2. Plasma Protein Market Forecast and Analysis
7.4. GROWTH FACTORS
7.4.1. Overview
7.4.2. Growth Factors Market Forecast and Analysis
7.5. FUSION PROTEINS
7.5.1. Overview
7.5.2. Fusion Proteins Market Forecast and Analysis
7.6. MONOCLONAL ANTIBODIES
7.6.1. Overview
7.6.2. Monoclonal Antibodies Market Forecast and Analysis
7.7. HORMONES
7.7.1. Overview
7.7.2. Hormones Market Forecast and Analysis
7.8. ENZYME
7.8.1. Overview
7.8.2. Enzyme Market Forecast and Analysis
7.9. COAGULATION FACTORS
7.9.1. Overview
7.9.2. Coagulation Factors Market Forecast and Analysis
7.10. OTHERS
7.10.1. Overview
7.10.2. Others Market Forecast and Analysis
8. RECOMBINANT THERAPEUTIC PROTEIN MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ONCOLOGY
8.3.1. Overview
8.3.2. Oncology Market Forecast and Analysis
8.4. HEMATOLOGY
8.4.1. Overview
8.4.2. Hematology Market Forecast and Analysis
8.5. IMMUNOLOGY
8.5.1. Overview
8.5.2. Immunology Market Forecast and Analysis
8.6. ENDOCRINOLOGY
8.6.1. Overview
8.6.2. Endocrinology Market Forecast and Analysis
8.7. CARDIOVASCULAR DISEASE
8.7.1. Overview
8.7.2. Cardiovascular Disease Market Forecast and Analysis
8.8. OTHERS
8.8.1. Overview
8.8.2. Others Market Forecast and Analysis
9. RECOMBINANT THERAPEUTIC PROTEIN MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Recombinant Therapeutic Protein Market Overview
9.1.2 North America Recombinant Therapeutic Protein Market Forecasts and Analysis
9.1.3 North America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.1.4 North America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.1.5 North America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.1.5.1 United States Recombinant Therapeutic Protein Market
9.1.5.1.1 United States Recombinant Therapeutic Protein Market by Drug Class
9.1.5.1.2 United States Recombinant Therapeutic Protein Market by Application
9.1.5.2 Canada Recombinant Therapeutic Protein Market
9.1.5.2.1 Canada Recombinant Therapeutic Protein Market by Drug Class
9.1.5.2.2 Canada Recombinant Therapeutic Protein Market by Application
9.1.5.3 Mexico Recombinant Therapeutic Protein Market
9.1.5.3.1 Mexico Recombinant Therapeutic Protein Market by Drug Class
9.1.5.3.2 Mexico Recombinant Therapeutic Protein Market by Application
9.2. EUROPE
9.2.1 Europe Recombinant Therapeutic Protein Market Overview
9.2.2 Europe Recombinant Therapeutic Protein Market Forecasts and Analysis
9.2.3 Europe Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.2.5 Europe Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Recombinant Therapeutic Protein Market
9.2.5.1.1 Germany Recombinant Therapeutic Protein Market by Drug Class
9.2.5.1.2 Germany Recombinant Therapeutic Protein Market by Application
9.2.5.2 France Recombinant Therapeutic Protein Market
9.2.5.2.1 France Recombinant Therapeutic Protein Market by Drug Class
9.2.5.2.2 France Recombinant Therapeutic Protein Market by Application
9.2.5.3 Italy Recombinant Therapeutic Protein Market
9.2.5.3.1 Italy Recombinant Therapeutic Protein Market by Drug Class
9.2.5.3.2 Italy Recombinant Therapeutic Protein Market by Application
9.2.5.4 Spain Recombinant Therapeutic Protein Market
9.2.5.4.1 Spain Recombinant Therapeutic Protein Market by Drug Class
9.2.5.4.2 Spain Recombinant Therapeutic Protein Market by Application
9.2.5.5 United Kingdom Recombinant Therapeutic Protein Market
9.2.5.5.1 United Kingdom Recombinant Therapeutic Protein Market by Drug Class
9.2.5.5.2 United Kingdom Recombinant Therapeutic Protein Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Recombinant Therapeutic Protein Market Overview
9.3.2 Asia-Pacific Recombinant Therapeutic Protein Market Forecasts and Analysis
9.3.3 Asia-Pacific Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Recombinant Therapeutic Protein Market
9.3.5.1.1 Australia Recombinant Therapeutic Protein Market by Drug Class
9.3.5.1.2 Australia Recombinant Therapeutic Protein Market by Application
9.3.5.2 China Recombinant Therapeutic Protein Market
9.3.5.2.1 China Recombinant Therapeutic Protein Market by Drug Class
9.3.5.2.2 China Recombinant Therapeutic Protein Market by Application
9.3.5.3 India Recombinant Therapeutic Protein Market
9.3.5.3.1 India Recombinant Therapeutic Protein Market by Drug Class
9.3.5.3.2 India Recombinant Therapeutic Protein Market by Application
9.3.5.4 Japan Recombinant Therapeutic Protein Market
9.3.5.4.1 Japan Recombinant Therapeutic Protein Market by Drug Class
9.3.5.4.2 Japan Recombinant Therapeutic Protein Market by Application
9.3.5.5 South Korea Recombinant Therapeutic Protein Market
9.3.5.5.1 South Korea Recombinant Therapeutic Protein Market by Drug Class
9.3.5.5.2 South Korea Recombinant Therapeutic Protein Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Recombinant Therapeutic Protein Market Overview
9.4.2 Middle East and Africa Recombinant Therapeutic Protein Market Forecasts and Analysis
9.4.3 Middle East and Africa Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Recombinant Therapeutic Protein Market
9.4.5.1.1 South Africa Recombinant Therapeutic Protein Market by Drug Class
9.4.5.1.2 South Africa Recombinant Therapeutic Protein Market by Application
9.4.5.2 Saudi Arabia Recombinant Therapeutic Protein Market
9.4.5.2.1 Saudi Arabia Recombinant Therapeutic Protein Market by Drug Class
9.4.5.2.2 Saudi Arabia Recombinant Therapeutic Protein Market by Application
9.4.5.3 U.A.E Recombinant Therapeutic Protein Market
9.4.5.3.1 U.A.E Recombinant Therapeutic Protein Market by Drug Class
9.4.5.3.2 U.A.E Recombinant Therapeutic Protein Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Recombinant Therapeutic Protein Market Overview
9.5.2 South and Central America Recombinant Therapeutic Protein Market Forecasts and Analysis
9.5.3 South and Central America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.5.5 South and Central America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Recombinant Therapeutic Protein Market
9.5.5.1.1 Brazil Recombinant Therapeutic Protein Market by Drug Class
9.5.5.1.2 Brazil Recombinant Therapeutic Protein Market by Application
9.5.5.2 Argentina Recombinant Therapeutic Protein Market
9.5.5.2.1 Argentina Recombinant Therapeutic Protein Market by Drug Class
9.5.5.2.2 Argentina Recombinant Therapeutic Protein Market by Application
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL RECOMBINANT THERAPEUTIC PROTEIN MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. RECOMBINANT THERAPEUTIC PROTEIN MARKET, KEY COMPANY PROFILES
12.1. BRISTOL-MYERS SQUIBB
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. CELLDEX THERAPEUTICS, INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ELI LILLY AND COMPANY
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. GLAXOSMITHKLINE PLC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. MERCK AND CO., INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. NOVARTIS INTERNATIONAL AG
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. SCHERING AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. JOHNSON AND JOHNSON
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Recombinant Therapeutic Protein Market - By Drug Class
1.3.2 Recombinant Therapeutic Protein Market - By Application
1.3.3 Recombinant Therapeutic Protein Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RECOMBINANT THERAPEUTIC PROTEIN MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RECOMBINANT THERAPEUTIC PROTEIN MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. RECOMBINANT THERAPEUTIC PROTEIN MARKET - GLOBAL MARKET ANALYSIS
6.1. RECOMBINANT THERAPEUTIC PROTEIN - GLOBAL MARKET OVERVIEW
6.2. RECOMBINANT THERAPEUTIC PROTEIN - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. RECOMBINANT THERAPEUTIC PROTEIN MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. PLASMA PROTEIN
7.3.1. Overview
7.3.2. Plasma Protein Market Forecast and Analysis
7.4. GROWTH FACTORS
7.4.1. Overview
7.4.2. Growth Factors Market Forecast and Analysis
7.5. FUSION PROTEINS
7.5.1. Overview
7.5.2. Fusion Proteins Market Forecast and Analysis
7.6. MONOCLONAL ANTIBODIES
7.6.1. Overview
7.6.2. Monoclonal Antibodies Market Forecast and Analysis
7.7. HORMONES
7.7.1. Overview
7.7.2. Hormones Market Forecast and Analysis
7.8. ENZYME
7.8.1. Overview
7.8.2. Enzyme Market Forecast and Analysis
7.9. COAGULATION FACTORS
7.9.1. Overview
7.9.2. Coagulation Factors Market Forecast and Analysis
7.10. OTHERS
7.10.1. Overview
7.10.2. Others Market Forecast and Analysis
8. RECOMBINANT THERAPEUTIC PROTEIN MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. ONCOLOGY
8.3.1. Overview
8.3.2. Oncology Market Forecast and Analysis
8.4. HEMATOLOGY
8.4.1. Overview
8.4.2. Hematology Market Forecast and Analysis
8.5. IMMUNOLOGY
8.5.1. Overview
8.5.2. Immunology Market Forecast and Analysis
8.6. ENDOCRINOLOGY
8.6.1. Overview
8.6.2. Endocrinology Market Forecast and Analysis
8.7. CARDIOVASCULAR DISEASE
8.7.1. Overview
8.7.2. Cardiovascular Disease Market Forecast and Analysis
8.8. OTHERS
8.8.1. Overview
8.8.2. Others Market Forecast and Analysis
9. RECOMBINANT THERAPEUTIC PROTEIN MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Recombinant Therapeutic Protein Market Overview
9.1.2 North America Recombinant Therapeutic Protein Market Forecasts and Analysis
9.1.3 North America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.1.4 North America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.1.5 North America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.1.5.1 United States Recombinant Therapeutic Protein Market
9.1.5.1.1 United States Recombinant Therapeutic Protein Market by Drug Class
9.1.5.1.2 United States Recombinant Therapeutic Protein Market by Application
9.1.5.2 Canada Recombinant Therapeutic Protein Market
9.1.5.2.1 Canada Recombinant Therapeutic Protein Market by Drug Class
9.1.5.2.2 Canada Recombinant Therapeutic Protein Market by Application
9.1.5.3 Mexico Recombinant Therapeutic Protein Market
9.1.5.3.1 Mexico Recombinant Therapeutic Protein Market by Drug Class
9.1.5.3.2 Mexico Recombinant Therapeutic Protein Market by Application
9.2. EUROPE
9.2.1 Europe Recombinant Therapeutic Protein Market Overview
9.2.2 Europe Recombinant Therapeutic Protein Market Forecasts and Analysis
9.2.3 Europe Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.2.5 Europe Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Recombinant Therapeutic Protein Market
9.2.5.1.1 Germany Recombinant Therapeutic Protein Market by Drug Class
9.2.5.1.2 Germany Recombinant Therapeutic Protein Market by Application
9.2.5.2 France Recombinant Therapeutic Protein Market
9.2.5.2.1 France Recombinant Therapeutic Protein Market by Drug Class
9.2.5.2.2 France Recombinant Therapeutic Protein Market by Application
9.2.5.3 Italy Recombinant Therapeutic Protein Market
9.2.5.3.1 Italy Recombinant Therapeutic Protein Market by Drug Class
9.2.5.3.2 Italy Recombinant Therapeutic Protein Market by Application
9.2.5.4 Spain Recombinant Therapeutic Protein Market
9.2.5.4.1 Spain Recombinant Therapeutic Protein Market by Drug Class
9.2.5.4.2 Spain Recombinant Therapeutic Protein Market by Application
9.2.5.5 United Kingdom Recombinant Therapeutic Protein Market
9.2.5.5.1 United Kingdom Recombinant Therapeutic Protein Market by Drug Class
9.2.5.5.2 United Kingdom Recombinant Therapeutic Protein Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Recombinant Therapeutic Protein Market Overview
9.3.2 Asia-Pacific Recombinant Therapeutic Protein Market Forecasts and Analysis
9.3.3 Asia-Pacific Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Recombinant Therapeutic Protein Market
9.3.5.1.1 Australia Recombinant Therapeutic Protein Market by Drug Class
9.3.5.1.2 Australia Recombinant Therapeutic Protein Market by Application
9.3.5.2 China Recombinant Therapeutic Protein Market
9.3.5.2.1 China Recombinant Therapeutic Protein Market by Drug Class
9.3.5.2.2 China Recombinant Therapeutic Protein Market by Application
9.3.5.3 India Recombinant Therapeutic Protein Market
9.3.5.3.1 India Recombinant Therapeutic Protein Market by Drug Class
9.3.5.3.2 India Recombinant Therapeutic Protein Market by Application
9.3.5.4 Japan Recombinant Therapeutic Protein Market
9.3.5.4.1 Japan Recombinant Therapeutic Protein Market by Drug Class
9.3.5.4.2 Japan Recombinant Therapeutic Protein Market by Application
9.3.5.5 South Korea Recombinant Therapeutic Protein Market
9.3.5.5.1 South Korea Recombinant Therapeutic Protein Market by Drug Class
9.3.5.5.2 South Korea Recombinant Therapeutic Protein Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Recombinant Therapeutic Protein Market Overview
9.4.2 Middle East and Africa Recombinant Therapeutic Protein Market Forecasts and Analysis
9.4.3 Middle East and Africa Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Recombinant Therapeutic Protein Market
9.4.5.1.1 South Africa Recombinant Therapeutic Protein Market by Drug Class
9.4.5.1.2 South Africa Recombinant Therapeutic Protein Market by Application
9.4.5.2 Saudi Arabia Recombinant Therapeutic Protein Market
9.4.5.2.1 Saudi Arabia Recombinant Therapeutic Protein Market by Drug Class
9.4.5.2.2 Saudi Arabia Recombinant Therapeutic Protein Market by Application
9.4.5.3 U.A.E Recombinant Therapeutic Protein Market
9.4.5.3.1 U.A.E Recombinant Therapeutic Protein Market by Drug Class
9.4.5.3.2 U.A.E Recombinant Therapeutic Protein Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Recombinant Therapeutic Protein Market Overview
9.5.2 South and Central America Recombinant Therapeutic Protein Market Forecasts and Analysis
9.5.3 South and Central America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Application
9.5.5 South and Central America Recombinant Therapeutic Protein Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Recombinant Therapeutic Protein Market
9.5.5.1.1 Brazil Recombinant Therapeutic Protein Market by Drug Class
9.5.5.1.2 Brazil Recombinant Therapeutic Protein Market by Application
9.5.5.2 Argentina Recombinant Therapeutic Protein Market
9.5.5.2.1 Argentina Recombinant Therapeutic Protein Market by Drug Class
9.5.5.2.2 Argentina Recombinant Therapeutic Protein Market by Application
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL RECOMBINANT THERAPEUTIC PROTEIN MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. RECOMBINANT THERAPEUTIC PROTEIN MARKET, KEY COMPANY PROFILES
12.1. BRISTOL-MYERS SQUIBB
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. CELLDEX THERAPEUTICS, INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ELI LILLY AND COMPANY
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. GLAXOSMITHKLINE PLC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. MERCK AND CO., INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. NOVARTIS INTERNATIONAL AG
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. SCHERING AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. JOHNSON AND JOHNSON
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies
1. Bristol-Myers Squibb
2. Celldex Therapeutics, Inc.
3. Eli Lilly and Company
4. GlaxoSmithKline plc
5. Merck & Co., Inc.
6. Novartis International AG
7. Schering AG
8. Johnson & Johnson
1. Bristol-Myers Squibb
2. Celldex Therapeutics, Inc.
3. Eli Lilly and Company
4. GlaxoSmithKline plc
5. Merck & Co., Inc.
6. Novartis International AG
7. Schering AG
8. Johnson & Johnson